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Detection of underling proteinopathies is becoming increasingly important across neuro-
degenerative conditions due to upcoming disease intervention trials. In this review, we ex-
plored how temporal lobe changes in amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) can potentially predict underlying TDP-43 pathology subtypes in FTD. To 
date, emphasis has been given to frontal lobe changes in the study of the cognitive and be-
havioural impairments in both syndromes but an increasing number of pathological, imaging 
and neuropsychological studies suggest how temporal lobe changes could critically affect 
the cognition and behaviour of these conditions. In this current article, we reviewed patho-
logical, imaging as well as clinical/neuropsychological findings of temporal involvement in the 
ALS-FTD continuum, how they relate to temporal lobe changes and the underlying TDP-43 
pathology in FTD. Findings across studies show that TDP-43 pathology occurs and coincides 
in many structures in ALS and FTD, but especially in the temporal lobes. In particular, anterior 
and medial temporal lobes atrophy is consistently found in ALS and FTD. In addition, memory 
and language impairment as well as emotional and Theory of Mind processing deficits that 
are characteristics of the two diseases are highly correlated to temporal lobe dysfunction. We 
conclude by showing that temporal lobe changes due to TDP-43 type B might be particular 
predictive of TDP-43 type B pathology in behavioural variant FTD, which clearly needs to be 
investigated further in the future.
Key words: Amyotrophic lateral sclerosis; Frontotemporal dementia; Memory; Temporal lobes
102 http://www.e-acn.org https://doi.org/10.14253/acn.2017.19.2.101
Annals of Clinical Neurophysiology Volume 19, Number 2, July 2017
INTRODUCTION
TDP-43 is one of the most common proteinopathies in neu-
rodegeneration and overlaps between many different clinical 
phenotypes. Still, it is not clear whether specific clinical or 
biomarker features overlap between these clinical syndromes, 
and in turn would allow detecting TDP-43 pathology in vivo. 
This is becoming particularly relevant with upcoming disease 
modifying therapies that will target the underling proteinop-
athy. In the current review, we will explore how such a view 
would apply to amyotrophic lateral sclerosis (ALS) and fron-
totemporal dementia (FTD), two different syndromes sharing 
many clinical features. More specifically, the majority of ALS 
patients have underlying TDP-43 pathology whereas in FTD 
there is a mix of underlying TDP-43 and tau pathology. The 
question arises whether based on the ALS findings one can 
determine which clinical features or biomarkers in FTD will be 
predictive of underling TDP-43 pathology. 
ALS is a progressive neurodegenerative disease affecting 
the motor neuron function. The clinical manifestation of ALS 
is characterized by progressive weakness concomitant with 
signs of spasticity, hyperreflexia, fasciculations and muscle 
wasting. Severe dysarthria and dysphagia is also commonly 
present and respiratory failure often leads to death in 3 to 5 
years.1 By contrast, FTD is a neurodegenerative disease char-
acterized by focal atrophy of frontal and temporal lobes.2 It 
is commonly regarded more as a cognitive or behavioural 
disease encompassing a behavioural variant (behavioural vari-
ant of frontotemporal dementia - bvFTD) and two language 
variants (semantic dementia – SD and progressive non-fluent 
aphasia - PNFA).3 Significant progressive changes in personali-
ty, behaviour and social cognition mainly characterizes bvFTD, 
while language impairments are the hallmark of SD and PNFA.4
Both ALS and FTD are multisystem neurodegenerative 
disorders with overlapping clinical and pathological charac-
teristics.5,6 Clinically, ALS and FTD patients can even present a 
combination of both syndromes (ALS-FTD) or develop symp-
toms of each other with disease progression.7 More specifical-
ly, ALS patients can present with behavioural/cognitive symp-
toms, whereas FTD patients can develop motor symptoms. 
Similarly, neuroimaging studies have reported anatomical 
changes in frontal, temporal and limbic areas for ALS, FTD and 
ALS-FTD patients as well as decreased integrity of gray matter 
(GM) and white matter (WM) in the frontal, temporal and pari-
etal lobes, including long association fibers.8,9
On a pathological level, it is well established that TDP-43 is 
the main pathology found in most of ALS cases.10-13 Interest-
ingly, TDP-43 is also one of the main pathologies (~50%) of 
FTD, in particular in SD as it accounts for 75% of the cases.14 
Although there are different subtypes of TDP-43 depositions, 
the presence of a shared proteinopathy reinforces the idea of 
a continuum across ALS and FTD. Convergences in the clini-
cal manifestations between them can be possibly attributed 
to the topographical distribution of the pathology in critical 
brain regions, especially in the frontotemporal network as 
TDP-43 in these regions have been particularly reported.15-17
There has been particular interest in the frontal changes in 
ALS and FTD to show how both diseases overlap for atrophy 
and clinical symptomology.10,18,19 Despite this shared overlap 
of frontal changes, these do not seem predictive of underly-
ing pathology in FTD.20 However, less emphasis has been giv-
en to the temporal lobe changes and how they might relate 
to TDP-43 proteinopathy. Since it is currently not possible to 
clinically distinguish the underlying pathology in FTD, as cases 
are an admixture of tau and TDP-43, being able to identify the 
pathology would have major implications for future disease 
intervention therapies targeting specific proteins. 
Whether temporal lobe changes can be predictive of TDP 
pathology, in particular Type B, in ALS and FTD is thus a critical 
question with a high clinical relevance. In order to explore this 
field, a Pubmed database search was performed using terms 
as ALS, FTD, TDP-43, temporal lobes (and related structures) 
and MRI. Only articles in English and presenting changes in 
temporal lobes were considered. In the following sections, 
we will explore temporal lobe changes in ALS and FTD from a 
multi-disciplinary angle, via neuropathological, neuroimaging 
and clinical/neuropsychological findings before attempting 
to synthesis the information towards the temporal lobe con-
tribution related to TDP-43 pathology.
TDP-43 PATHOLOGY IN THE ALS-FTD 
CONTINUUM
Neurodegenerative diseases are characterized by the pres-
ence of abnormal intracellular protein aggregates in the 
brain.10  TDP-43 depositions are specially found in ALS, FTD 
and ALS-FTD patients. Based on the morphologic appearanc-
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es and anatomical distribution of the immunoreactive inclu-
sions, TDP pathology is classified as being of type A, B, C or D.21
The vast majority of ALS cases is associated with TDP-43 
type B pathology.13,16 TDP-43 deposition is reported to be first 
accumulated across the motor system before spreading to 
the temporal lobes.22,23 Brettschneider and colleagues23 pro-
posed a TDP-43 staging scheme from 1 to 4 to account for 
spatial and temporal development of the pathology, consid-
ering TDP stage 4 when the pathology is also present in the 
hippocampal formation. 
TDP pathology in bvFTD is initiated in the orbitofrontal cor-
tex and amygdala, progressing then to frontal and temporal 
cortices before affecting the motor system, visual cortex and 
cerebellum.22,24,25 bvFTD patients are associated with TDP 
type A and B, with type A involving the frontal, temporal and 
parietal lobes and type B, the hippocampus.20,21,26 However, 
it is still not possible to clinically distinguish between types A 
and B.27 In a recent study on bvFTD with TDP-43 pathology, 
100% of the cases investigated showed TDP-43 in the amyg-
dala and the majority had the pathology in the medial tem-
poral lobe (MTL; dentate gyrus and entorhinal cortex). TDP 
pathology is particularly reported in SD, with TDP-43 type C 
associated to anterior temporal lobe (ATL) atrophy and with 
type A and, more important, type B in ALS-FTD.16,20,21,28
In addition, it is suggested that the C9orf72 gene mutation 
is the most frequent cause of familial ALS and FTD and ac-
counts for up to 10% of sporadic ALS cases.29,30 The temporal 
lobes are shown to be critically affected in C9orf72 patients 31 
linked to TDP-43 pathology types A and B.32
In sum, ALS and FTD could be considered as different 
manifestations of a shared proteinopathy.16 Although the 
presence of TDP pathology in some structures can help to 
distinguish between the disorders, the pathology coincide in 
many regions and reinforce the idea of a continuum across 
the diseases. In particular, immunoreactive inclusions of TDP-
43 in the amygdala, parahippocampal gyrus, hippocampus, as 
well as in other temporal lobe structures have been reported 
in both conditions.23,25,33
Neuroimaging findings 
Voxel based morphometry (VBM)
Atrophy of the temporal lobes in ALS, FTD and ALS-FTD have 
been well documented.5,34-37 ALS patients show temporal 
lobe atrophy, including ATL, hippocampal formation and 
left temporal gyrus.7,38-40 In bvFTD patients, temporal lobe 
atrophy, particularly in temporal poles, temporal gyrus, hip-
pocampus, parahippocampal cortices and amygdala have 
been reported.41-46 Temporal atrophy is also characteristic 
of SD with marked atrophy of ATL, temporal poles, fusiform 
gyrus, amygdaloid complex and temporal gyrus.3,47-49 Lillo 
and colleagues6 have reported atrophy of temporal regions 
in both bvFTD and ALS-FTD with no significant differences 
between these two diseases. ALS-FTD patients have shown 
temporal atrophy, including the ATL, temporal gyrus, hip-
pocampus and amygdala.5,18,47,50 Interestingly, temporal 
atrophy dominance is found in ALS-FTD compared with 
pure ALS patients.51 Supplementary Table 1 (Supplementa-
ry material) summarizes the most common areas with GM 
changes reported in the literature for ALS and FTD (results 
include VBM and other analyses).
Diffusion tensor imaging (DTI)
DTI analyses consistently report WM changes in tracts con-
necting temporal lobes to frontal and occipital regions in 
ALS patients, specifically, the uncinate fasciculus and supe-
rior longitudinal fasciculus.52-54Atrophy in temporal regions 
for both bvFTD and SD has been reported with WM changes 
found to be particularly important in the uncinate and lon-
gitudinal fasciculus.2,55-57 Atrophy in the inferior longitudinal 
fasciculus has been observed in ALS-FTD.6 ALS and ALS-
FTD patients showed more WM degeneration than bvFTD, 
including in the temporal poles.6 ALS, bvFTD and ALS-FTD 
showed overlapping WM degeneration in the inferior longi-
tudinal fasciculus.6 Supplementary Table 2 (Supplementary 
material) shows common areas with WM changes found in 
the literature for the ALS-FTD spectrum (results include DTI 
and other analyses).
Functional imaging
Positron emission tomography (PET) with Fluoro-Desoxy-Glu-
cose (FDG) studies found hypermetabolism in the tempo-
ral poles, superior temporal gyri and hippocampus in ALS 
patients.58 FTD patients showed metabolic impairment in 
temporal lobes.59 In more details, hypometabolism was 
found in temporal regions in bvFTD.41,60 In SD, hypometab-
olism was found in anterior poles, hippocampal region and 
fusiform gyrus.61-63 Metabolic changes in ALS-FTD patients 
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corresponded well with structural changes observed in extra 
motor areas with hypometabolism reported in the temporal 
lobes.30,50 
Despite specific patterns of atrophy in each of the syn-
dromes, ALS and FTD show many common areas of atrophy. 
Taken together, these imaging findings support the notion 
that ALS and FTD overlap in their neural correlates although 
some regions may be more affected than others in each of 
the diseases. Table 1 presents a summary of common find-
ings related to the temporal lobes regarding pathology, ana-
tomical changes and neuropsychological deficits.
Clinical/Neuropsychological findings 
Behaviour/social cognition
Temporal lobe changes are most commonly associated with 
episodic and semantic memory, as well as social cognition 
symptoms, and social inappropriateness among other fea-
tures consistent with the Klüver-Bucy syndrome are docu-
mented in animals and humans with temporal lobe dam-
age.64,65 Interestingly, FTD patients are often reported with 
features closely similar to this syndrome,28,66-69 and although 
less common in ALS patients, the syndrome or some of its 
features have also been reported.70 Still, the contributions 
of temporal changes on behavioural symptoms have been 
little explored so far in ALS or FTD. 
ToM deficits in ALS and FTD patients are reported in the 
literature and correlated to frontal lobe change.71-74 Howev-
er, an increasing number of studies also support the critical 
involvement of temporal lobe structures in successful social 
functioning.75-77 Recently, ToM deficits have been correlated 
to changes in temporal regions, including temporal gyrus, 
temporal poles and MTL in SD patients in both cognitive and 
affective tasks78-80 and in bvFTD, including right temporal fusi-
form cortex, temporal pole, hippocampus and amygdala.80
Investigations of cognitive deficits in ALS, FTD and ALS-FTD 
patients have been found to covary with reduction of GM in 
several regions of the temporal lobes, including the hippo-
campal formation and amygdala as well as a loss of integrity 
of the WM networks connecting frontotemporal areas to pa-
rietal and occipital areas, including uncinate and longitudinal 
fasciculus.9,54,81-93
Episodic memory
Amnesia, in particular, is problematic as a symptom in ALS 
and FTD, as it is currently considered as the diagnosis gold 
standard for underlying Alzheimer’s disease pathophysiology. 
By contrast, episodic memory is considered to be preserved in 
the ALS-FTD spectrum and therefore, severe amnesia is even 
stated as a diagnostic exclusion criterion for the behavioural 
variant of FTD.68 Contradicting this classical view that mem-
ory is relatively spared in ALS and FTD patients, a growing 
number of studies have recently reported severe and genu-
ine memory impairments in these disorders.72,94-96 Indeed, a 
good proportion of pathologically confirmed FTD patients 
show significant episodic memory problems, indicating that 
MTL areas, particularly hippocampal and parahippocampal 
regions, are clearly affected in the syndrome 43,45,46,97 and that 
Table 1. Summary of overlapping findings in ALS and FTD
Cognitive deficits WM atrophy GM atrophy
TDP 
pathology 
Memory 
Linguistic 
abilities
Emotion 
recognition
ToM deficits ILF, CC AC, UnF, SLF FOR, IC, CR TP, PrG, FG, HF, A Subtype
ALS + + + – + + + + B
bvFTD + + + + + + + + A, B
SD + + + + + + – + C
ALS-FTD + + – – + – – + A, B
ALS, amyotrophic lateral sclerosis; FTD; frontotemporal dementia; WM, white matter; GM, gray matter; TDP, TDP-43; ToM, theory of mind; ILF, inferior longi-
tudinal fasciculus; CC, corpus callosum; AC, anterior commissure; UnF, uncinate fasciculus; SLF, superior longitudinal fasciculus; FOR, fornix; IC, internal cap-
sula; CR, corona radiata; TP, temporal pole; PrG, parahippocampal gyrus; FG, fusiform gyrus; HF, hippocampal formation; A, amygdala; bvFTD, behavioural 
variant FTD; SD, semantic dementia; +, affected; –, not reported.
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executive dysfunctions caused by frontal atrophy are not the 
main contributor of memory impairment in FTD.43 As for ALS, 
memory deficits have been controversial and most studies 
link memory impairment to executive dysfunction.81,98,99 
However, recent studies report authentic episodic memory 
deficits and implicate MTL structures, showing that memory 
impairment in non-demented ALS patients is not exclusively 
a disturbance of the executive functioning.52,82,83,88,100-103 
Semantic memory
Semantic memory is the knowledge of everyday objects and 
events and its loss is attributed to the deterioration of the 
ATL.61,104 In particular, the temporal poles, the most anterior 
part of the ATL, are proposed to have a general function to 
form the basis of semantic memory and is also linked to face 
recognition, processing of auditory, olfactory and visual stim-
uli and ToM processing.77 ALS and FTD patients have been 
found to present with semantic memory deficits.47,49,62,105,106
Still in the semantic domain, deficits in linguistic abilities 
and social communication have been recently reported in 
ALS patients found with structural and functional temporal 
lobe changes.47,90,107,108 Phukan and colleagues102 found that 
14% of non-demented ALS patients presented with cognitive 
impairment, including language deficits, but without exec-
utive dysfunction. Language impairments  have also been 
found in bvFTD and SD patients, and executive deficits did 
not fully account for the impairments but also temporal lobe 
atrophy.49,109-111 ALS-FTD patients have also shown impair-
ment in linguistic processing.47 
Emotion recognition
Finally, both ALS and FTD patients present with emotion 
recognition deficits.37,93,110-118 The main area involved in 
emotion face processing is the amygdala, also shown to 
be strongly involved in emotional memories, learning and 
recall.113-115,119-123 The amygdala has been proposed as a crit-
ical nexus modulating memory processing.124 Interestingly, 
the structure is often seen as central to TDP-43 pathology 
and thus might provide a critical insight into the underlying 
pathology.25 In addition to face processing deficits, sarcasm 
recognition, a social ability associated to the temporal lobes 
is reported to be impaired in both non-demented ALS and 
FTD patients.125,126
Conclusions and future directions
Structures of the temporal lobes have shown overlapping 
anatomical changes in ALS, FTD and ALS-FTD.32,47,51,116 
Specifically, the temporal poles and the MTL are found 
with anatomical changes consistently reported in this con-
tinuum.43,127-129 Beyond the MTL involvement, particularly 
hippocampal and parahippocampal regions, the amygdala 
appeared to be a critical structure identified with anatomical 
changes affecting both ALS and FTD patients.130,131
The knowledge of the cognitive and behavioural impair-
ments in ALS and FTD has developed substantially over the 
past decades. The description of the phenotypic variation 
found across ALS and FTD patients, in combination with im-
aging and post mortem pathological findings strengthen the 
contemporary approach of a clinical spectrum between these 
diseases. It is increasingly clear that these two conditions 
form a continuum of clinical manifestations of the same pro-
teinopathy linked to TDP-43 abnormalities, and the sympto-
mology can be highly related to temporal lobe function. The 
evidences presented in this article demonstrate the critical 
contribution of the temporal lobe pathology to the features 
presented by the patients. The relationship between abnor-
mal TDP-43 deposition and anatomical/functional changes in 
the temporal lobes should be further investigated to better 
define the correlation with cognitive and neuropsychiatric 
symptoms, especially in the ALS cases where impaired mem-
ory and social behaviour is controversial and therefore have 
been underestimated or not thoroughly investigated. Further 
studies investigating social cognition, memory and behaviour 
are needed to better characterize ALS and to fully understand 
its clinical overlap with FTD. The contribution that ATL and 
MTL atrophy could, respectively, have on social cognition and 
memory deficits in ALS and FTD should also be investigated 
further by imaging studies that should take into account and 
control the already well-described executive and frontal defi-
cits that characterize these diseases and could influence both 
cognitive domains. Finally, post-mortem studies on FTD and 
ALS should contrast cases with TDP-43 and other pathology 
in order to find the better clinical, cognitive and anatomical 
markers of TDP-43 pathology. Clinicians should increase the 
information delivered to patients about the usefulness of 
brain donations and their practical aspects. In addition, public 
services should communicate more widely about these do-
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nations and then increase knowledge critical for the develop-
ment of future treatments. 
It is worth noting that TDP-43 type B is critically involved 
in most ALS, bvFTD and ALS-FTD cases, suggesting that the 
temporal lobe changes reported in these conditions, especial-
ly in the hippocampal regions and amygdala could be predic-
tive of this pathology type in bvFTD. Further investigation on 
the origin and nature of the cognitive impairments and the 
pathological TDP-43 expression behind them, in conjunction 
with neuroimaging techniques will shed light to the mecha-
nisms of the diseases, potentially improve diagnosis of bvFTD 
and contribute to the development of new drugs targeting 
specifically TDP-43 type B. Fostering on these results, novel 
neuropsychological tests tapping specifically into these tem-
poral lobes functions would likely help the diagnosis and the 
assessment of these new drugs.
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